Top

Published in:

01-04-2012 | General Gynecology

Hormone replacement therapy leads to increased plasma levels of platelet derived microparticles in postmenopausal women

Authors: Andreas Rank, Rienk Nieuwland, Katharina Nikolajek, Sabine Rösner, Lisa-Maria Wallwiener, Erhard Hiller, Bettina Toth

Published in: Archives of Gynecology and Obstetrics | Issue 4/2012

Abstract

Background

Whereas prevention of cardiovascular diseases by hormonal replacement therapy is still part of an ongoing debate, well-defined data are available relating hormonal replacement therapy to an elevated risk of venous thrombosis and embolism. Although it seems that venous thrombosis in patients treated with hormonal replacement therapy is linked to changes in plasmatic coagulation, less is known about the role of platelet-derived microparticles, as well as endothelial cell-derived microparticles.

Patients and methods

In this prospective case–control study, levels of microparticles were investigated in postmenopausal women receiving hormone replacement therapy (n = 15) and compared to age-matched controls (n = 15).

Results

Total count of microparticles and the subgroup of microparticles derived from endothelial cells did not differ in the investigated groups. In contrast, median levels of microparticles derived from platelet/megacaryocyte were higher in women taking hormonal replacement therapy (5,244 × 10⁶/l) than in controls (2,803 × 10⁶/l; p = 0.040). Furthermore, hormonal replacement therapy led to a higher plasma level of microparticles derived from activated platelets, exposing P-selectin (136 × 10⁶/l vs. 58 × 10⁶/l; p = 0.011), or exposing CD63 (171 × 10⁶ vs. 91 × 10⁶/l; p = 0.011) compared to the control group.

Conclusion

Higher concentrations of microparticles derived from (activated) platelets/megacaryocytes were present in postmenopausal women taking hormonal replacement therapy. This finding indicates a procoagulant state in these women and might play a role in the development of venous side effects. In contrast, levels of endothelial cell-derived microparticles did not differ.

Hickey M, Davis SR, Sturdee DW (2005) Treatment of menopausal symptoms: what shall we do now? Lancet 366:409–421PubMedCrossRef

Bagger YZ, Tanko LB, Alexandersen P, Hansen HB, Mollgaard A, Ravn P, Qvist P, Kanis JA, Christiansen C (2004) Two to three years of hormone replacement treatment in healthy women have long-term preventive effects on bone mass and osteoporotic fractures: the PERF study. Bone 34:728–735PubMedCrossRef

(1997) Collaborative Group on Hormonal Factors in Breast Cancer: breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet 350:1047–1059

Bath P, Gray LJ (2005) Association between hormone replacement therapy and subsequent stroke: a meta analysis. BMJ 330:342PubMedCrossRef

Canonico M, Plu-Bureau G, Lowe GD, Scarabin PY (2008) Hormone replacement therapy and risk for venous thromboembolism in postmenopausal women: systematic review and meta-analysis. BMJ 336(7655):1227–1231PubMedCrossRef

Sandset PM, Høibraaten E, Eilertsen AL, Dahm A (2009) Mechanisms of thrombosis related to hormone therapy. Thromb Res 123(Suppl 2):S70–S73PubMedCrossRef

Scarabin PY, Oger E, Plu-Bureau G, Estrogen and Thromboembolism Risk Study Group (2003) Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk. Lancet 362(9382):428–432PubMedCrossRef

Høibraaten E, Mowinckel MC, de Ronde H, Bertina RM, Sandset PM (2001) Hormone replacement therapy and acquired resistance to activated protein C: results of a randomized, double-blind, placebo-controlled trial. Br J Haematol 115(2):415–420PubMedCrossRef

Rosano GM, Vitale C, Fini M (2006) Hormone replacement therapy and cardioprotection: what is good and what is bad for the cardiovascular system? Ann N Y Acad Sci 1092:341–348PubMedCrossRef

10.

Arnal JF, Douin-Echinard V, Tremollières F (2007) Understanding the controversy about hormonal replacement therapy: insights from estrogen effects on experimental and clinical atherosclerosis. Arch Mal Coeur Vaiss 100:554–562PubMed

11.

Stevenson J (2009) HRT and cardiovascular disease. Best Pract Res Clin Obstet Gynaecol 23(1):109–120PubMedCrossRef

12.

Gokkusu C, Tata G, Ademoğlu E, Tamer S (2010) The benefits of hormone replacement therapy on plasma and platelet antioxidant status and fatty acid composition in healthy postmenopausal women. Platelets 21(6):439–444PubMedCrossRef

13.

Signorelli SS, Sciacchitano S, Di Pino L, Costa MP, Pennisi G, Caschetto S (2001) Effects of long-term hormone replacement therapy on arterial wall thickness, lipids and lipoproteins, fibrinogen and antithrombin III. Gynecol Endocrinol 15(5):367–372PubMed

14.

Schindler TH, Campisi R, Dorsey D (2009) Effect of hormone replacement therapy on vasomotor function of the coronary microcirculation in post-menopausal women with medically treated cardiovascular risk factors. Eur Heart J 30(8):978–986PubMedCrossRef

15.

Iwamoto S, Kawasaki T, Kambayashi J, Ariyoshi H, Shinoki N, Sakon M, Ikeda Y, Monden M (1997) The release mechanism of platelet-activating factor during shear-stress induced platelet aggregation. Biochem Biophys Res Commun 239(1):101–105PubMedCrossRef

16.

Cramer EM, Norol F, Guichard J, Breton-Gorius J, Vainchenker W, Massé JM, Debili N (1997) Ultrastructure of platelet formation by human megakaryocytes cultured with the Mpl ligand. Blood 89:2336–2346PubMed

17.

Nieuwland R, Berckmans RJ, Rotteveel-Eijkman RC, Maquelin KN, Roozendaal KJ, Jansen PG, ten Have K, Eijsman L, Hack CE, Sturk A (1997) Cell-derived microparticles generated in patients during cardiopulmonary bypass are highly procoagulant. Circulation 96:3534–3541PubMed

18.

Sims PJ, Faioni EM, Wiedmer T, Shattil SJ (1988) Complement proteins C5b-9 cause release of membrane vesicles from the platelet surface that are enriched in the membrane receptor for coagulation factor Va and express prothrombinase activity. J Biol Chem 263:18205–18212PubMed

19.

Biró E, Sturk-Maquelin KN, Vogel GM, Meuleman DG, Smit MJ, Hack CE, Sturk A, Nieuwland R (2003) Human cell-derived microparticles promote thrombus formation in vivo in a tissue factor-dependent manner. J Thromb Haemost 1(12):2561–2568PubMedCrossRef

20.

Sinauridze EI, Kireev DA, Popenko NY, Pichugin AV, Panteleev MA, Krymskaya OV, Ataullakhanov FI (2007) Platelet microparticle membranes have 50- to 100-fold higher specific procoagulant activity than activated platelets. Thromb Haemost 97(3):425–434PubMed

21.

Gemmell CH, Sefton MV, Yeo EL (1993) Platelet-derived microparticle formation involves glycoprotein IIb–IIIa. Inhibition by RGDS and a Glanzmann’s thrombasthenia defect. J Biol Chem atherothrombotic disease. J Biol Chem 268(20):14586–14589PubMed

22.

Sims PJ, Wiedmer T, Esmon CT, Weiss HJ, Shattil SJ (1988) Assembly of the platelet prothrombinase complex is linked to vesiculation of the platelet plasma membrane. Studies in Scott syndrome: an isolated defect in platelet procoagulant activity. J Biol Chem 264(29):17049–17057

23.

Kuriyama N, Nagakane Y, Hosomi A, Ohara T, Kasai T, Harada S, Takeda K, Yamada K, Ozasa K, Tokuda T, Watanabe Y, Mizuno T, Nakagawa M (2010) Evaluation of factors associated with elevated levels of platelet-derived microparticles in the acute phase of cerebral infarction. Clin Appl Thromb Hemost 16(1):26–32PubMedCrossRef

24.

Li X, Cong H (2009) Platelet-derived microparticles and the potential of glycoprotein IIb/IIIa antagonists in treating acute coronary syndrome. Tex Heart Inst J 36(2):134–139PubMed

25.

Joop K, Berckmans RJ, Nieuwland R, Berkhout J, Romijn FP, Hack CE, Sturk A (2001) Microparticles from patients with multiple organ dysfunction syndrome and sepsis support coagulation through multiple mechanisms. Thromb Haemost 85(5):810–820PubMed

26.

Kelton JG (2002) Heparin-induced thrombocytopenia: an overview. Blood Rev 16(1):77–80PubMedCrossRef

27.

Myers DD, Hawley AE, Farris DM, Wrobleski SK, Thanaporn P, Schaub RG, Wagner DD, Kumar A, Wakefield TW (2003) P-selectin and leukocyte microparticles are associated with venous thrombogenesis. J Vasc Surg 38(5):1075–1089PubMedCrossRef

28.

Jimenez JJ, Jy W, Mauro LM, Soderland C, Horstman LL, Ahn YS (2003) Endothelial cells release phenotypically and quantitatively distinct microparticles in activation and apoptosis. Thromb Res 109(4):175–180PubMedCrossRef

29.

Abid Hussein MN, Meesters EW, Osmanovic N, Romijn FP, Nieuwland R, Sturk A (2003) Antigenic characterization of endothelial cell-derived microparticles and their detection ex vivo. J Thromb Haemost 1(11):2434–2443PubMedCrossRef

30.

Berckmans RJ, Nieuwland R, Böing AN, Romijn FP, Hack CE, Sturk A (2001) Cell-derived microparticles circulate in healthy humans and support low grade thrombin generation. Thromb Haemost 83:639–646

31.

Bal L, Ederhy S, Di Angelantonio E, Toti F, Zobairi F, Dufaitre G, Meuleman C, Mallat Z, Boccara F, Tedgui A, Freyssinet JM, Cohen A (2010) Factors influencing the level of circulating procoagulant microparticles in acute pulmonary embolism. Arch Cardiovasc Dis 103(6–7):394–403PubMedCrossRef

32.

Rectenwald JE, Myers DD Jr, Hawley AE, Longo C, Henke PK, Guire KE, Schmaier AH, Wakefield TW (2005) D-dimer, P-selectin, and microparticles: novel markers to predict deep venous thrombosis. A pilot study. Thromb Haemost 94(6):1312–1317PubMed

33.

Ramacciotti E, Hawley AE, Farris DM, Ballard NE, Wrobleski SK, Myers DD Jr, Henke PK, Wakefield TW (2009) Leukocyte- and platelet-derived microparticles correlate with thrombus weight and tissue factor activity in an experimental mouse model of venous thrombosis. Thromb Haemost 101(4):748–754PubMed

34.

Rank A, Nieuwland R, Crispin A, Gr Tzner S, Iberer M, Toth B, Pihusch R (2011) Clearance of platelet microparticles in vivo. Platelets 22(2):111–116PubMedCrossRef

35.

Warren BA, Vales O (1972) The release of vesicles from platelets following adhesion to vessel walls in vitro. Br J Exp Pathol 53:206–215PubMed

36.

Miyazaki Y, Nomura S, Miyake T, Kagawa H, Kitada C, Taniguchi H, Komiyama Y, Fujimura Y, Ikeda Y, Fukuhara S (1996) High shear stress can initiate both platelet aggregation and shedding of procoagulant containing microparticles. Blood 88:3456–3464PubMed

37.

Heijnen HF, Schiel AE, Fijnheer R, Geuze HJ, Sixma JJ (1999) Activated platelets release two types of membrane vesicles: microvesicles by surface shedding and exosomes derived from exocytosis of multivesicular bodies and alpha-granules. Blood 94:3791–3799PubMed

38.

van der Zee PM, Biró E, Ko Y, de Winter RJ, Hack CE, Sturk A, Nieuwland R (2006) P-selectin- and CD63-exposing platelet microparticles reflect platelet activation in peripheral arterial disease and myocardial infarction. Clin Chem 52(4):657–664PubMedCrossRef

39.

Tan KT, Tayebjee MH, Lynd C, Blann AD, Lip GY (2005) Platelet microparticles and soluble P selectin in peripheral artery disease: relationship to extent of disease and platelet activation markers. Ann Med 37(1):61–66PubMedCrossRef

40.

Travlos GS (2006) Normal structure, function, and histology of the bone marrow. Toxicol Pathol 34:548–565PubMedCrossRef

41.

Flaumenhaft R, Dilks JR, Richardson J, Alden E, Patel-Hett SR, Battinelli E, Klement GL, Sola-Visner M, Italiano JE Jr (2009) Megakaryocyte-derived microparticles: direct visualization and distinction from platelet-derived microparticles. Blood 113:1112–1121PubMedCrossRef

42.

Rank A, Nieuwland R, Delker R, Köhler A, Toth B, Pihusch V, Wilkowski R, Pihusch R (2010) Cellular origin of platelet-derived microparticles in vivo. Thromb Res 126(4):255–259CrossRef

43.

Tarantino MD, Kunicki TJ, Nugent DJ (1994) The estrogen receptor is present in human megakaryocytes. Ann N Y Acad Sci 714:293–296PubMedCrossRef

44.

Nagata Y, Yoshikawa J, Hashimoto A, Yamamoto M, Payne AH, Todokoro K (2003) Proplatelet formation of megakaryocytes is triggered by autocrine-synthesized estradiol. Genes Dev 17(23):2864–2869PubMedCrossRef

45.

Stevens RF, Alexander MK (1977) A sex difference in the platelet count. Br J Haematol 37(2):295–300PubMedCrossRef

46.

Toth B, Nikolajek K, Rank A, Nieuwland R, Lohse P, Pihusch V, Friese K, Thaler CJ (2007) Gender-specific and menstrual cycle dependent differences in circulating microparticles. Platelets 18(7):515–521PubMedCrossRef

47.

Corada M, Liao F, Lindgren M, Lampugnani MG, Breviario F, Frank R, Muller WA, Hicklin DJ, Bohlen P, Dejana E (2001) Monoclonal antibodies directed to different regions of vascular endothelial cadherin extracellular domain affect adhesion and clustering of the protein and modulate endothelial permeability. Blood 97(6):1679–1684PubMedCrossRef

48.

Simak J, Holada K, Risitano AM, Zivny JH, Young NS, Vostal JG (2004) Elevated circulating endothelial membrane microparticles in paroxysmal nocturnal haemoglobinuria. Brit J Haematol 125(6):804–813CrossRef

49.

Koga H, Sugiyama S, Kugiyama K, Watanabe K, Fukushima H, Tanaka T, Sakamoto T, Yoshimura M, Jinnouchi H, Ogawa H (2005) Elevated levels of VE-cadherin-positive endothelial microparticles in patients with type 2 diabetes mellitus and coronary artery disease. J Am Coll Cardiol 45:1622–1630PubMedCrossRef

50.

Wakefield TW, Henke PK (2005) The role of inflammation in early and late venous thrombosis: are there clinical implications? Semin Vasc Surg 18(3):118–129PubMedCrossRef

Title: Hormone replacement therapy leads to increased plasma levels of platelet derived microparticles in postmenopausal women
Authors: Andreas Rank
Rienk Nieuwland
Katharina Nikolajek
Sabine Rösner
Lisa-Maria Wallwiener
Erhard Hiller
Bettina Toth
Publication date: 01-04-2012
Publisher: Springer-Verlag
Published in: Archives of Gynecology and Obstetrics / Issue 4/2012
Print ISSN: 0932-0067
Electronic ISSN: 1432-0711
DOI: https://doi.org/10.1007/s00404-011-2098-0

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Hormone replacement therapy leads to increased plasma levels of platelet derived microparticles in postmenopausal women

Abstract

Background

Patients and methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Patients and methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 4/2012

Mature cystic teratomas in our series with review of the literature and retrospective analysis

Induction of labor in prolonged pregnancy with unfavorable cervix: comparison of sequential intracervical Foley catheter–intravaginal misoprostol and intravaginal misoprostol alone

Uterine-sparing surgical management of postpartum hemorrhage: is it always effective?

Submental lymph node metastasis from invasive ductal breast carcinoma

Cellular blue nevus of the vulva mimicking Bartholin’s gland abscess in a 15-year-old girl: a case report

Laparoscopic pelvic lymphadenectomy: experience of a Gynaecological Cancer Centre in the UK